Articles published by BioInvent International

BioInvent Moves to NASDAQ Stockholm’s Mid Cap Segment

December 20, 2021

From BioInvent International

Via AccessWire

BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab

December 17, 2021

From BioInvent International

Via AccessWire

BioInvent’s Latest NHL Data at ASH Show Increased and Sustained Responses to BI-1206 in Relapsed Patients

December 11, 2021

From BioInvent International

Via AccessWire

BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China

December 10, 2021

From BioInvent International

Via AccessWire

Tickers CASI

BioInvent has Submitted a CTA for a Phase 1/2a trial of BI-1607, a Novel anti-FcyRIIB Antibody for the Treatment of Patients with Solid Tumors

December 08, 2021

From BioInvent International

Via AccessWire

Nomination Committee Appointed for BioInvent International’s Annual General Meeting 2022

November 25, 2021

From BioInvent International

Via AccessWire

BioInvent Hosting Key Opinion Leader Webinar on BI-1206

November 23, 2021

From BioInvent International

Via AccessWire

BioInvent and Transgene present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021

November 09, 2021

From BioInvent International

Via AccessWire

Topics Artificial Intelligence

BioInvent to Show Further Positive BI-1206 Clinical Data in December at ASH 2021

November 04, 2021

From BioInvent International

Via AccessWire

Invitation to Presentation of BioInvent’s Interim Report January–September 2021

October 28, 2021

From BioInvent International

Via AccessWire

BioInvent International AB Interim Report January - September 2021

October 28, 2021

From BioInvent International

Via AccessWire

BioInvent Appoints Immunotherapy Expert Alexander Eggermont to Scientific Advisory Board

October 25, 2021

From BioInvent International

Via AccessWire

BioInvent and Transgene to present preclinical data on BT-001 oncolytic virus at SITC 2021

October 01, 2021

From BioInvent International

Via AccessWire

Topics Artificial Intelligence

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.